Psilocybine services in Oregon: a call for awareness among clinical toxicologists.
Clinical toxicology (Philadelphia, Pa.) March 1, 2023 DOI: 10.1080/15563650.2023.2182664 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Intervention | Psilocybine |
| Keywords | Psilocybine Adverse event Toxicology Psychedelics hallucinogens Entheogens Public health healthcare Community health Population health Risk management Patient monitoring |
| Citations | 6 |
| Key points | Argues that Oregon's psilocybine regulatory framework raises issues regarding non-clinical facilitator scope, adverse event management, and dosing uncertainties for individuals with medical conditions. |
Abstract
In 2023, Oregon enacted laws regulating the manufacture and use of psilocybine products in licensed facilities for supervised sessions with trained facilitators. This commentary summarizes the final rules for psilocybine services in Oregon, and provides perspectives from a clinical toxicologist on some of the issues that may arise. These include the scope of practice for non-clinical facilitators, prevention and management of adverse drug reactions, and toxicological uncertainties with regards to dose considerations for people with mental health and other medical conditions. This commentary addresses some common misperceptions relating to the program, and provides perspective on some of the challenges that clinical toxicologists may encounter as legislative reform initiatives for psilocybine move forward throughout the United States.